Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	AZD-6482	2	72	sigmoid	sigmoid	BT20 AZD6482 0 2 72	8	1.645	0.581	0.0253	0.303	3.86	-1.0	0.58	0.904	0.000884	NA	1.34	0.333	0.772	1.34	0.0	0.582	0.864	0.0025	NA
BT-549	TGX221	1	72	sigmoid	sigmoid	BT549 TGX-221 0 1 72	8	1.826	Inf	0.821	0.0771	0.297	0.777	0.632	0.868	0.00232	NA	Inf	0.842	0.931	0.313	0.799	0.603	0.863	0.00255	NA
BT-549	AS605240	1	72	sigmoid	sigmoid	BT549 AS-605240 0 1 72	8	1.804	Inf	0.893	0.0436	4.49	0.778	0.375	0.862	0.00261	NA	Inf	0.905	0.961	4.52	0.804	0.371	0.861	0.00267	NA
BT-549	Everolimus	1	72	sigmoid	sigmoid	BT549 everolimus 0 1 72	8	1.772	5.64	0.503	0.444	1e-05	0.367	0.1	0.911	0.000706	NA	437200.0	0.603	0.641	0.000146	0.444	0.1	0.858	0.00286	NA
BT-549	CAL-101	3	72	sigmoid	sigmoid	BT549 idelalisib 0 3 72	8	1.770	43.0	0.79	0.0687	320.0	-0.664	0.421	0.862	0.00261	NA	118.0	0.822	0.941	118.0	0.0	0.425	0.854	0.00309	NA
BT-20	AS605240	1	72	sigmoid	sigmoid	BT20 AS-605240 0 1 72	8	2.142	Inf	0.817	0.0993	3.91	0.634	0.244	0.861	0.00271	NA	Inf	0.814	0.897	3.87	0.629	0.237	0.854	0.00311	NA
Hs 578T	Sirolimus	1		sigmoid	sigmoid	Hs578T rapamycin 1	8	2.013	110643.0	0.587	0.358	0.000237	0.432	0.1	0.879	0.00178	NA	9.61e+11	0.628	0.672	0.000175	0.487	0.1	0.851	0.00332	NA
BT-549	KIN001-244	1	72	sigmoid	sigmoid	BT549 KIN001-244 0 1 72	8	1.802	Inf	0.872	0.0273	4.85	0.695	0.794	0.852	0.00324	NA	Inf	0.888	0.976	4.84	0.733	0.786	0.846	0.00362	NA
HCC38	AZD-6482	3	72	sigmoid	sigmoid	HCC38 AZD6482 0 3 72	8	1.420	Inf	0.821	0.0615	0.324	0.826	5.0	0.849	0.00342	NA	Inf	0.875	0.957	0.323	0.879	5.0	0.846	0.00367	NA
BT-20	AS605240	2	72	sigmoid	sigmoid	BT20 AS-605240 0 2 72	8	1.846	4509270.0	0.729	0.203	320.0	0.31	0.101	0.845	0.00373	NA	4.4e+12	0.764	0.821	56.5	0.46	0.101	0.843	0.00388	NA
Hs 578T	KIN001-244	3		sigmoid	sigmoid	Hs578T KIN001-244 3	8	2.888	Inf	0.866	0.00909	5.05	0.617	1.35	0.858	0.00289	NA	50.0	0.818	0.988	5.2	0.474	1.31	0.842	0.00391	NA
HCC1806	PIK-93	1	72	sigmoid	sigmoid	HCC1806 PIK-93 0 1 72	8	2.753	44.0	0.853	0.0391	304.0	-1.0	0.568	0.858	0.00285	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
HCC1806	PIK-93	2	72	sigmoid	sigmoid	HCC1806 PIK-93 0 2 72	8	2.838	41.1	0.857	0.038	265.0	-1.0	0.59	0.858	0.00286	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
HCC1806	PIK-93	3	72	sigmoid	sigmoid	HCC1806 PIK-93 0 3 72	8	3.206	56.0	0.873	0.0337	320.0	-0.872	0.579	0.859	0.00279	NA	46.6	0.811	0.948	46.6	0.0	0.57	0.84	0.00406	NA
HCC38	MK2206	3	72	sigmoid	sigmoid	HCC38 MK-2206 0 3 72	8	1.445	71.7	0.728	0.123	320.0	-0.26	0.28	0.854	0.0031	NA	Inf	0.81	0.912	4.3	0.61	0.332	0.834	0.00461	NA
HCC70	PIK-93	3	72	sigmoid	sigmoid	HCC70 PIK-93 0 3 72	8	2.519	21.2	0.756	0.0663	181.0	-1.0	0.513	0.851	0.00333	NA	34.1	0.721	0.92	34.1	0.0	0.473	0.831	0.00487	NA
HCC38	AZD-6482	2	72	sigmoid	sigmoid	HCC38 AZD6482 0 2 72	8	2.132	Inf	0.898	0.0351	4.71	0.773	0.497	0.824	0.0055	NA	Inf	0.894	0.963	4.7	0.765	0.492	0.82	0.00588	NA
HCC38	XL147	3	72	sigmoid	sigmoid	HCC38 pilaralisib 0 3 72	8	1.420	Inf	0.909	0.0219	0.114	0.921	5.0	0.815	0.00631	NA	Inf	0.936	0.985	0.114	0.945	5.0	0.813	0.00654	NA
BT-549	MK2206	2	72	sigmoid	sigmoid	BT549 MK-2206 0 2 72	8	1.871	Inf	0.926	0.0188	0.107	0.926	5.0	0.816	0.00627	NA	Inf	0.932	0.983	0.107	0.931	5.0	0.809	0.00694	NA
BT-549	Sirolimus	1	72	sigmoid	sigmoid	BT549 rapamycin 0 1 72	8	1.817	3.62	0.51	0.438	0.000148	0.318	0.1	0.87	0.00218	NA	506850.0	0.6	0.638	8.82e-05	0.447	0.1	0.8	0.00802	NA
BT-20	Alpelisib	3	72	sigmoid	sigmoid	BT20 alpelisib 0 3 72	8	2.541	1.21	0.199	0.21	5.83	-1.0	0.697	0.881	0.00167	NA	1.12	0.272	0.775	1.12	0.0	0.764	0.791	0.00916	NA
HCC1806	Pictilisib	3	72	sigmoid	sigmoid	HCC1806 pictilisib 0 3 72	8	3.234	14.1	0.818	0.0423	52.2	-0.98	0.831	0.814	0.00649	NA	11.3	0.734	0.935	11.3	0.0	0.849	0.773	0.0116	NA
HCC1806	Pictilisib	1	72	sigmoid	sigmoid	HCC1806 pictilisib 0 1 72	8	2.782	11.7	0.79	0.049	43.7	-1.0	0.831	0.811	0.00677	NA	11.3	0.734	0.935	11.3	0.0	0.849	0.773	0.0116	NA
HCC1806	Pictilisib	2	72	sigmoid	sigmoid	HCC1806 pictilisib 0 2 72	8	2.866	12.1	0.796	0.0476	45.4	-1.0	0.831	0.811	0.00671	NA	11.3	0.734	0.935	11.3	0.0	0.849	0.773	0.0116	NA
BT-20	PIK-93	2	72	sigmoid	sigmoid	BT20 PIK-93 0 2 72	8	1.798	0.792	0.155	0.286	14.1	-1.0	0.382	0.81	0.00687	NA	2.8	0.373	0.764	2.8	0.0	0.344	0.77	0.0121	NA

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)